Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study

Overview of attention for article published in Gastroenterology, March 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 10 news outlets
twitter: 11 X users
patent: 3 patents
facebook: 1 Facebook page

guideline: 2 clinical guideline sources
bluesky: 2 Bluesky users
podcasts: 1 podcast

Readers on

mendeley: 74 Mendeley

So far, Altmetric has seen 2 Bluesky posts from 2 Bluesky users, with an upper bound of 890 followers.

Study examines the efficacy and safety of guselkumab subcutaneous induction and maintenance in participants with moderately to severely active #CrohnsDisease. Read the full article here: ow.ly/vXaT50Wzy2X

7/ 📌 Takeaway GRAVITI shows subcutaneous guselkumab is: ✅ Effective (Week 12 + 48) ✅ Safe ✅ Patient-friendly (no IV) 💥 A new option in the IBD toolbox — especially for those preferring SC route. www.gastrojournal.org/article/S001... @amergastroas…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.